Karl Peggs is a Professor of Transplant Science and Cancer Immunotherapy, Scientific Director NIHR Blood and Transplant Research Unit for Stem Cells and Immunotherapies, Scientific Co-Chair and Board Member of the British Society of Blood and Marrow Transplantation, and Honorary Consultant in Haematology/Stem Cell Transplantation at UCLH; he is also an Honorary Consultant (non-clinical) at the Royal Marsden Hospital, London. After taking the position of Senior Lecturer at UCL in 2003 and Head of Adult Stem Cell Transplantation Services, UCLH, he spent over 2 years at MSKCC, NYC, USA in the laboratory of Professor James Allison studying murine models of regulatory checkpoint blockade. He runs a joint Research Laboratory with Dr Sergio Quezada in the UCL Cancer Institute and his research interests include viral infections, immune reconstitution, adoptive cellular therapies, and regulatory checkpoint-directed immune-therapeutics. More recently he has established the clinical translational side of the academic CAR T cell programme at UCLH.

 Karl Peggs is a Professor of Transplant Science and Cancer Immunotherapy, Scientific Director NIHR Blood and Transplant Research Unit for Stem Cells and Immunotherapies, Scientific Co-Chair and Board Member of the British Society of Blood and Marrow Transplantation, and Honorary Consultant in Haematology/Stem Cell Transplantation at UCLH; he is also an Honorary Consultant (non-clinical) at the Royal Marsden Hospital, London. After taking the position of Senior Lecturer at UCL in 2003 and Head of Adult Stem Cell Transplantation Services, UCLH, he spent over 2 years at MSKCC, NYC, USA in the laboratory of Professor James Allison studying murine models of regulatory checkpoint blockade. He runs a joint Research Laboratory with Dr Sergio Quezada in the UCL Cancer Institute and his research interests include viral infections, immune reconstitution, adoptive cellular therapies, and regulatory checkpoint-directed immune-therapeutics. More recently he has established the clinical translational side of the academic CAR T cell programme at UCLH.